Levodopa is the preferred treatment for Parkinson's disease in the clinic. However, long-term use of levodopa may lead to various motor complications, among which levodopa-induced dyskinesia is the most common, severely affecting patients' quality of life. Dr. Jiancheng He and co-workers from Shanghai University of Traditional Chinese Medicine in China established a model of Parkinson's disease dyskinesia in rats, and treated these animals with Compound Formula Rehmannia. They found that Compound Formula Rehmannia alleviates levodopa-induced dyskinesia in Parkinson's disease by modulating neurotransmitter signaling in the corpus striatum. The relevant article has been published in the Neural Regeneration Research (Vol. 9, No. 4, 2014).